Jennifer Onwochei, MD
Transplant Hepatology · Manhasset, NYNPI 1710349410
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 34.8% of the total. Reporting peaked in 2022 at $653 and has fallen 74.8% since, to $165 in 2024. That places this record below the midpoint for transplant hepatology clinicians in NY, where the typical reported total is $1,622.
Across 19 payments — averaging $83.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$552
- Gilead$290
- Intercept Pharmaceuticals, Inc.$249
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$150
- Sanofi$135
- E.r. Squibb & Sons, L.L.C.$123
- plus $89 from 2 others
What the payments were for
- Food & beverage$1,581100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 9 | $552 |
| Gilead | 3 | $290 |
| Intercept Pharmaceuticals, Inc. | 2 | $249 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $150 |
| Sanofi | 1 | $135 |
| E.r. Squibb & Sons, L.L.C. | 1 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $58 |
| Boston Scientific | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,588 in reported general payments places this provider in the 45th percentile of 36 transplant hepatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Entecavir | 17 | $8,172 |
| Ursodiol | 26 | $2,950 |
| Spironolactone | 24 | $200 |
| Furosemide | 19 | $103 |
Paid to pharmacies, not to this prescriber.
Other transplant hepatology in Manhasset
- Harmit KaliaManhasset$21K
- Nitzan RothManhasset$58
- Nikolaos PyrsopoulosNew York$251K
- James ParkNew York$81K
- Amon AsgharpourNew York$58K
- Giuseppe CullaroNew York$50K
- Julia WattacherilNew York$37K
- Gene ImNew York$15K
- Elizabeth VernaNew York$11K
- Rajani SharmaNew York$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.